Related Experiment Video

Updated: Jun 19, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Discovering Biomarkers and Pathways Shared by Alzheimer's Disease and Ischemic Stroke to Identify Novel Therapeutic

Md Rezanur Rahman1, Tania Islam2, Md Shahjaman3

  • 1Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Sirajgonj 6751, Bangladesh. rezanur12@yahoo.com.

Medicina (Kaunas, Lithuania)
|May 25, 2019
PubMed

Insights

Researchers identified common molecular links between Alzheimer's disease (AD) and ischemic strokes (IS). This study reveals shared gene expression patterns and pathways, offering new insights into disease progression and potential therapeutic targets for both conditions.

Area of Science:

  • Neuroscience
  • Genomics
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing severe dementia.
  • Ischemic strokes (IS) are recognized risk factors for AD, yet underlying molecular mechanisms remain unclear.
  • Understanding shared molecular pathways is crucial for predicting disease progression and identifying therapeutic targets.

Purpose of the Study:

  • To identify common molecular biomarkers and pathways in both ischemic strokes (IS) and Alzheimer's disease (AD).
  • To elucidate potential mechanistic and gene expression links between IS and AD.
  • To discover novel therapeutic strategies by analyzing protein-drug interactions.

Main Methods:

  • Analysis of microarray gene expression datasets for IS and AD.
  • Application of combinatorial statistical methods to identify commonly dysregulated transcripts.
  • Utilized Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) analyses.

Main Results:

  • Identified 26 common dysregulated transcripts (22 unique genes) in IS and AD.
  • Revealed altered molecular pathways including MAPK signaling, alcoholism, and amino acid metabolism.
  • Identified key pathway hub proteins (e.g., PDE9A, GNAO1) and transcription factors (e.g., SPIB, SMAD3).

Conclusions:

  • Established novel putative links between IS and AD at the transcript level.
  • Highlighted PDE9A as a potential therapeutic target with interactions to caffeine and other compounds.
  • Provided foundational insights into the shared molecular pathology of IS and AD.

Keywords:
Alzheimer’s diseasebiomarker signaturesdifferentially expressed genesdrug targetsischemic strokeprotein–drug interactionsprotein–protein interaction

More Related Videos

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model08:22

Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model

Published on: June 20, 2025

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...